Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 5/20 | 0.64 |
| ▸ | ABCC8 | Q09428 | 5/20 | 0.64 |
| ▸ | KCNJ11 | Q14654 | 5/20 | 0.64 |
| ▸ | KCNJ8 | Q15842 | 5/20 | 0.64 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.61 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.61 |
| ▸ | AR | P10275 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15359209 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL15359210 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL7515733 | 0.88 | ABCC9 (0.68) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL2481947 | 0.86 | AR (0.61) | AR | |
| SCHEMBL7518469 | 0.84 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL12050119 | 0.83 | AR (0.58) | AR | |
| SCHEMBL31053809 | 0.83 | AR (0.58) | AR | |
| SCHEMBL11031351 | 0.83 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL7512834 | 0.83 | PDK1 (0.69) | ABCC9ABCC8KCNJ11KCNJ8PDK1 | |
| SCHEMBL19964399 | 0.82 | AR (0.65) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0886515-B1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | OREAL (FR) | 2002-01-16 | — | — | EP | claimed |
| US-6291532-B1 | Use of N-aryl-2-hydroxyalkylamides for stimulating or inducing hair growth and/or arresting hair loss | L'OREAL (FR) | 2001-09-18 | — | — | US | claimed |
| EP-0886515-A1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | L'OREAL (FR) | 1998-12-30 | — | — | EP | claimed |
| WO-1997032562-A1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | L'OREAL (FR) | 1997-09-12 | — | — | WO | claimed |
| EP-3129786-A1 | SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTYPES | Arno Therapeutics Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157343-A1 | SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTYPES | ARNO THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157343-A1 | SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTYPES | ARNO THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150285803-A1 | SYSTEMS AND METHODS FOR IDENTIFYING PROGESTERONE RECEPTOR SUBTYPES | INVIVIS PHARMACEUTICALS INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150276767-A1 | SYSTEMS AND METHODS FOR IDENTIFYING CANCERS HAVING ACTIVATED PROGESTERONE RECEPTORS | THE UNIVERSITY OF SYDNEY (AU) | 2015-10-01 | — | — | US | disclosed |
| US-20140363425-A1 | SYSTEMS AND METHODS FOR IDENTIFYING CANCERS HAVING ACTIVATED PROGESTERONE RECEPTORS | GRAHAM J DINNY (AU) | 2014-12-11 | — | — | US | disclosed |
| WO-2013162776-A1 | BREAST CANCER PROGNOSIS, PREDICTION OF PROGESTERONE RECEPTOR SUBTYPE AND|PREDICTION OF RESPONSE TO ANTIPROGESTIN TREATMENT BASED ON GENE EXPRESSION | LANGE CAROL (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-0886515-B1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | OREAL (FR) | 2002-01-16 | — | — | EP | disclosed |
| US-6291532-B1 | Use of N-aryl-2-hydroxyalkylamides for stimulating or inducing hair growth and/or arresting hair loss | L'OREAL (FR) | 2001-09-18 | — | — | US | disclosed |
| EP-0886515-A1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | L'OREAL (FR) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997032562-A1 | USE OF N-ARYL-2-HYDROXYALKYLAMIDES FOR STIMULATING OR INDUCING HAIR GROWTH AND/OR ARRESTING HAIR LOSS | L'OREAL (FR) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150276767-A1 | SYSTEMS AND METHODS FOR IDENTIFYING CANCERS HAVING ACTIVATED PROGESTERONE RECEPTORS | PGR, PGRMC2, PGRMC1 | ABCC9 4230/4885ABCC8 3806/4885KCNJ11 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.